English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Investigators provided open-label remdesivir on a compassionate-use basis to patients hospitalised with severe COVID-19, an illness caused by infection with SARSCoV-2. Severity was defi ned as an oxygen saturation of 94% or less while patients were breathing ambient air or receiving oxygen support. Patients with contraindications for remdesivir, including creatinine clearance below 30 ml/min and elevated liver enzymes beyond fi ve times upper limit of normal, were excluded. Patients received a 10-day course of intravenous remdesivir, starting with loading dose of 200 mg administered intravenously on day one, followed by 100 mg daily for the remaining nine days.

Have We Found the Panacea to Covid-19 with Remdesivir, An Old but Newly Packaged Drug?